Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H13N5O5S2 |
Molecular Weight | 383.403 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C3=CSC(N)=N3)C(O)=O
InChI
InChIKey=NNULBSISHYWZJU-LLKWHZGFSA-N
InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
Molecular Formula | C13H13N5O5S2 |
Molecular Weight | 383.403 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Ceftizoxime is a semisynthetic cephalosporin antibiotic, which can be administered intravenously or intramuscularly. It was sold under brand name, cefizox, but was removed from the US Market in 2007. Cefizox was used to treat different infections, such as lower respiratory tract infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenza; urinary tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. Also for treatment of gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae; pelvic inflammatory disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae; meningitis caused by Haemophilus influenza. In addition, some others infections. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae. Infections caused by aerobic gram ¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. The bactericidal action of ceftizoxime results from inhibition of the third and last stage of bacterial cell wall synthesis. Bacterial cell wall autolytic enzymes such as autolysins then mediate cell lysis; it is possible that ceftizoxime interferes with an autolysin inhibitor. Ceftizoxime is highly resistant to a broad spectrum of beta -lactamases (penicillinase and cephalosporinase), including Richmond types II, III, TEM, IV, produced by both aerobic and anaerobic gram - positive and gram - negative organisms and I.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2582913
Curator's Comment: Ceftizoxime was undetectable or its concentration very low in the cerebrospinal fluid (CSF), when there was no inflammation in the meninges.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7018389 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CEFIZOX Approved UseCefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae.
Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. Launch Date1983 |
|||
Curative | CEFIZOX Approved UseCefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae.
Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. Launch Date1983 |
|||
Curative | CEFIZOX Approved UseCefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae.
Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. Launch Date1983 |
|||
Curative | CEFIZOX Approved UseCefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae.
Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. Launch Date1983 |
|||
Curative | CEFIZOX Approved UseCefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase¬ and nonpenicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae, but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Pseudomonas spp. including P.aeruginosa; Proteus mirabilis; P. vulgaris; Providencia rettgeri (formerly Proteus rettgeri) and Morganella morganii (formerly Proteus morganii); Klebsiella spp.; Serratia spp. including S. marcescens; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae. Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae. NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti¬chlamydial coverage should be added. Intra¬Abdominal Infections caused by Escherichia coli; Staphylococcusepidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Escherichia coli; Bacteroides spp. including B. fragilis; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Staphylococcus epidermidis; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase¬ and nonpenicillinase¬producing); Streptococcus spp. (excluding enterococci); Proteusmirabilis; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae.
Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram¬negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. Launch Date1983 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34721 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26896348 |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFTIZOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6296034 |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFTIZOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
68631 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26896348 |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFTIZOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6296034 |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFTIZOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26896348 |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFTIZOXIME serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg/kg 1 times / day steady, intravenous Studied dose Dose: 100 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 100 mg/kg, 1 times / day Sources: |
unhealthy, 1 month-18 years n = 1 Health Status: unhealthy Age Group: 1 month-18 years Population Size: 1 Sources: |
|
500 mg single, intramuscular Studied dose Dose: 500 mg Route: intramuscular Route: single Dose: 500 mg Sources: |
healthy, 25- 43 years |
|
2 g 2 times / day steady, intravenous Studied dose Dose: 2 g, 2 times / day Route: intravenous Route: steady Dose: 2 g, 2 times / day Sources: |
unhealthy Health Status: unhealthy Condition: complicated urinary tract infections Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16098483/ Page: 4.0 |
yes [IC50 3598.6 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16098483/ Page: 4.0 |
yes [IC50 956.7 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics. | 1985 Jan |
|
Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. | 1985 Jan |
|
[A comparative, well-controlled study of ceftizoxime suppository against ceftizoxime intravenous injection in infantile acute pneumonia]. | 1986 May |
|
Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. | 1987 Oct |
|
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources. | 1990 Jul |
|
First two cases of immune hemolytic anemia associated with ceftizoxime. | 1999 Aug |
Sample Use Guides
The usual adult dosage is 1 or 2 grams of Cefizox (ceftizoxime for injection, USP) every 8 to 12 hours. Proper dosage and route of administration should be determined by the condition of the patient, severity of the infection, and susceptibility of the causative organisms.
Uncomplicated Urinary Tract - 1 grams; 500 mg q12h IM or IV
Severe or Refractory - 3-6 grams; 1 gram q8h IM or IV; 2 grams q8-12h IM or IV
Because of the serious nature of urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. A single, 1 gram IM dose is the usual dose for treatment of uncomplicated gonorrhea. The IV route may be preferable for patients with bacterial septicemia, localized parenchymal abscesses (such as intra¬abdominal abscess), peritonitis, or other severe or life¬threatening infections. In those with normal renal function, the IV dosage for such infections is 2 to 12 grams of Cefizox (ceftizoxime for injection, USP) daily. In conditions such as bacterial septicemia, 6 to 12 grams/day may be given initially by the IV route for several days, and the dosage may then be gradually reduced according to clinical response and laboratory findings.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3302857
The in vitro activity of ceftizoxime was tested by determining minimal inhibitory concentrations (MIC) by agar dilution method, for 150 strains of genus Pasteurella and group EF4 bacteria from various sources. All the strains were susceptible to ceftizoxime and inhibited by 0.03 micrograms/ml concentration. No significant difference appeared between the 7 species and human and animal strains. Group EF4 bacteria, frequently isolated from animal bite wounds in humans, had higher MIC (O.25-1 micrograms/ml).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:23:54 GMT 2023
by
admin
on
Fri Dec 15 15:23:54 GMT 2023
|
Record UNII |
C43C467DPE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
LIVERTOX |
NBK547862
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
LIVERTOX |
NBK548666
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
WHO-VATC |
QJ01DD07
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
WHO-ATC |
J01DD07
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
563
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
4743
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
100000082061
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
C43C467DPE
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL528
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
68401-81-0
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
2192
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
Ceftizoxime
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
m3222
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
6533629
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
1098173
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
C61668
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
Ceftizoxime
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
DTXSID5022772
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
DB01332
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
C43C467DPE
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
553473
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
SUB07429MIG
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY | |||
|
D015296
Created by
admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||